🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Innovative Multidisciplinary Strategies for Combating Severe Dengue

Recruitingn/aAges 18 Years - anyAllKarolinska Institutet
NCT06751836 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to identify biomarkers and host factors associated with dengue severity in patients from dengue-endemic regions. The main question it aims to answer is: Can multi-omics approaches predict disease severity and identify key factors contributing to severe dengue infections? Participants will include individuals with dengue infection, and the study will analyze their blood samples using multi-omics techniques to uncover host immune responses, disease pathogenesis, and cellular pathway interactions. The study will also assess the role of primary and secondary infections, virus serotypes, and immunological factors in disease progression. Findings aim to support disease management, improve severity prediction, and identify potential therapeutic targets to prevent severe outcomes.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Group 1: Dengue without warning signs Patients presenting with the following symptoms confirmed positive for dengue infection by lab diagnosis by anti-dengue IgM or NS1 ELISA will be recruited for the study under this cohort. Symptoms will be fever along with at least two of the following - * Myalgia, arthralgia * Nausea and/or vomiting * Rashes * Leukopenia Group 2: DENV with warning signs This cohort will include patients with the above symptoms and any of the following clinical signs. * Abdominal pain with tenderness * Persistent vomiting * Fluid accumulation * Mucosal bleeding * Restlessness, lethargy * Liver enlargement \>2cm * Laboratory findings: An increase in hematocrit levels and a rapid decrease in platelet count Group 3: Severe dengue * Severe plasma leakage leads to hypovolemic shock (dengue shock syndrome) and fluid accumulation with respiratory distress. * Severe bleeding, such as epistaxis, internal bleeding, etc., is evaluated by a clinician. * Severe organ involvement with any of the following symptoms * Liver AST or ALT ≥ 1000 * CNS: impaired consciousness * Heart and other organs failure Exclusion Criteria: \-
💊

What it tests

  • Infection and no infection
📍

Where

2 sites
Bio Box Guatemala Ong de Investigación, Servicios Y de Medio Ambiente
Guatemala City, Guatemala
Manipal Academy of Higher Education (MAHE)
Mangalore, India
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy